Volume 23, Issue 6

Search all Investigational New Drugs articles

December 2005

Special Issue: Recent Advances in Pharmacogenetic Approaches to Cancer Chemotherapy

Issue Editors:

Alex Sparreboom,
William D. Figg

14 articles in this issue

Introduction
Alex Sparreboom, Guest Editor
William D. Figg
OriginalPaper 26 October 2005 Pages: 511 - 511
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
Ron H. N. van Schaik
OriginalPaper 26 October 2005 Pages: 513 - 522
The thiopurines: An update
Sally Coulthard
Linda Hogarth
OriginalPaper 26 October 2005 Pages: 523 - 532
Thymidylate synthase pharmacogenetics
Sharon Marsh
OriginalPaper 26 October 2005 Pages: 533 - 537
Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan
Maki Ando
Yoshinori Hasegawa
Yuichi Ando
OriginalPaper 26 October 2005 Pages: 539 - 545
Growth Inhibition and Apoptosis-Induced Effect on Human Cancer Cells of Toosendanin, a Triterpenoid Derivative from Chinese Traditional Medicine
Bin Zhang
Zhong-Feng Wang
Yu-Liang Shi
OriginalPaper Pages: 547 - 553
A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors
G. A. Otterson
J. Lavelle
M. Grever
OriginalPaper Pages: 555 - 562
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer
Afshin Dowlati
Robert Chapman
Scot C. Remick
OriginalPaper Pages: 563 - 567
Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma
D Scott Ernst
Elizabeth Eisenhauer
Michael Smylie
OriginalPaper Pages: 569 - 575
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma
Philip E. Shaheen
Walter Stadler
Ronald M. Bukowski
OriginalPaper Pages: 577 - 581
A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
Basil F. El-Rayes
Mark M. Zalupski
Philip A. Philip
OriginalPaper Pages: 583 - 590
Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea
Marc Webster
Gregory Cairncross
Elizabeth Eisenhauer
OriginalPaper Pages: 591 - 596
Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination
Emilio Esteban-Gonzalez
Yolanda Fernández
Angel J. Lacave
OriginalPaper Pages: 597 - 601
Erratum
Tsavaris
Erratum 20 December 2005 Pages: 603 - 603

Volume 23, Issue 6

Introduction

Cancer treatment and pharmacogenetics of cytochrome P450 enzymes

The thiopurines: An update

Thymidylate synthase pharmacogenetics

Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan

Growth Inhibition and Apoptosis-Induced Effect on Human Cancer Cells of Toosendanin, a Triterpenoid Derivative from Chinese Traditional Medicine

A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma

A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

Erratum

Navigation